|
|
|
|
Bone Marrow Transplant Procedures News
|
|
|
|
|
|
|
All Recent Bone Marrow Transplant Procedures News |
|
|
|
|
Oncology Nursing Society Foundation Josh Gottheil Memorial Bone Marrow Transplant Career Development Awards
Supported by the Josh Gottheil Memorial Fund for Lymphoma Research
Award: Four $2,000 awards and plaques.
Purpose: To support a professional registered nurse for meritorious practice in BMT nursing by providing financial assistance to attend a continuing education program(s) that will further the nurses' professional goals, or to supplement tuition in a bachelors or masters program.
Selection Criteria:
* Currently employed as a registered nurse working in bone marrow transplantation with a minimum of 75% time devoted to patient care, or in the position of nurse manager, nurse practitioner, or clinical nurse specialist with BMT patient population or a BMT coordinator.
* Two or more years in BMT nursing practice prior to application due date.
* An individual cannot receive t......
POSTED 08/30/2010 at 06:00 PM --
|
BiopsyâDiagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues
We report the results of 105 renal biopsies from 101 nonrenal transplant recipients (bone marrow 14, liver 41, lung 30, heart 20). Biopsy indications were protracted acute renal failure (9%), creatinine increases (83%), heavy proteinuria (22%), or renal insufficiency before reâtransplantation (9%). Histological findings other than nonspecific chronic changes, hypertensionârelated damage, and signs of chronic CNI toxicity included primary glomerular disease (17%), mostly after liver transplantation (21%) or after bone marrow transplantation (29%), and thrombotic microangiopathy (TMA) namely (10%). TMA had the most serious impact on the clinical course. Besides severe hypertension, one TMA patient died of cerebral hemorrhage, 5 had hemolyticâuremic syndrome, and 6 rapidly developed end......
POSTED 08/28/2010 at 04:01 AM --
|
Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation
Abstract: Regulatory T cells (Tregs) can prevent graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT). Here we developed a lentivirus-based strategy to ectopically express Foxp3 in mouse CD4+CD25â T cells. These cells shared similar immunophenotypes and biological features of natural Tregs. Co-injection of engineered Tregs with donor bone marrow cells and splenocytes prevented recipients from lethal GVHD. Furthermore, we showed that graft-versus-leukemia (GVL) effect against EL4/DsRed leukemic cells was maximally preserved while GVHD was minimized during exposure to engineered Tregs in a mouse leukemia model. These findings provide a novel approach to preventing GVHD while maintaining GVL effect during BMT. (Source: Leukemia Research)...
POSTED 08/27/2010 at 01:28 AM --
|
Factor IX ectopically expressed in platelets can be stored in {alpha}-granules and corrects the phenotype of hemophilia B mice
We developed 2bF9 transgenic mice in a hemophilia B mouse model with the expression of human factor IX (FIX) under control of the platelet-specific integrin IIb promoter, to determine whether ectopically expressing FIX in megakaryocytes can enable the storage of FIX in platelet -granules and corrects the murine hemophilia B phenotype. FIX was detected in the platelets and plasma of 2bF9 transgenic mice by both antigen and activity assays. Approximately 90% of total FIX in blood was stored in platelets, most of which is releasable on activation of platelets. Immunostaining demonstrated that FIX was expressed in platelets and megakaryocytes and stored in -granules. All 2bF9 transgenic mice survived tail clipping, suggesting that platelet-derived FIX normalizes hemostasis in the hemophilia B ......
POSTED 08/26/2010 at 11:02 AM --
|
What is the minimum level of donor chimerism necessary to sustain transfusion independence in thalassaemia?
What is the minimum level of donor chimerism necessary to sustain transfusion independence in thalassaemia?
Bone Marrow Transplantation advance online publication, August 23, 2010. doi:10.1038/bmt.2010.186
Authors: A Alfred
& A J Vora (Source: Bone Marrow Transplantation)...
POSTED 08/22/2010 at 06:00 PM --
|
Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma
Authors: W J Plattel, H C Kluin-Nelemans, G H de Bock
& G W van Imhoff (Source: Bone Marrow Transplantation)...
POSTED 08/22/2010 at 06:00 PM --
|
Progression of a CD4+/CD56+ blastic plasmacytoid DC neoplasm after initiation of extracorporeal photopheresis in an allogeneic transplant recipient
Progression of a CD4+/CD56+ blastic plasmacytoid DC neoplasm after initiation of extracorporeal photopheresis in an allogeneic transplant recipient
Bone Marrow Transplantation advance online publication, August 23, 2010. doi:10.1038/bmt.2010.196
Authors: A Dohm, J Hasenkamp, H P Bertsch, J H Maas, L Truemper
& G Wulf (Source: Bone Marrow Transplantation)...
POSTED 08/22/2010 at 06:00 PM --
|
Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients
Authors: B L McClune, L E Polgreen, L A Burmeister, A H Blaes, D A Mulrooney, L J Burns
& N S Majhail (Source: Bone Marrow Transplantation)...
POSTED 08/22/2010 at 06:00 PM --
|
Augmentation of the Antileukemia Potency of Total-Body Irradiation (TBI) by a Novel P-site Inhibitor of Spleen Tyrosine Kinase (SYK).
Authors: Uckun FM, Dibirdik I, Qazi S
Abstract A novel spleen tyrosine kinase (SYK) P-site inhibitor, 1,4-Bis (9-O dihydroquinidinyl) phthalazine/hydroquinidine 1,4-phathalazinediyl diether (C-61), (but not vehicle) markedly enhanced H(2)O(2)-induced apoptosis of primary leukemia cells from each of five relapsed B-lineage acute lymphoblastic leukemia (ALL) patients, as measured by in vitro TUNEL assays. A highly radiation-resistant subclone of the murine B-lineage leukemia cell line BCL-1 was next used to investigate the in vivo radiosensitizing effects of C-61. C-61 enhanced the antileukemia potency of 7 Gy total-body irradiation (TBI) in the context of syngeneic bone marrow transplantation (BMT) at 20% of its nonobservable adverse effect level (NOAEL) that does not exhibit detectable......
POSTED 08/22/2010 at 06:00 PM --
|
HIV-resistant cells work in mice. Can they help humans?
California scientists, boosted by stem cell research funding enabled by Proposition 71, are aiming for clinical trials involving gene therapy through bone marrow transplants.Clad in a yellow gown, blue foot covers, hair net, face mask and latex gloves, Paula Cannon pushed open the door to the animal room. "I hate this smell," she said, wrinkling her nose. (Source: Los Angeles Times - Science)...
POSTED 08/21/2010 at 08:44 PM --
|
HIV-resistant cells work in mice. Can they help humans?
California scientists, boosted by stem cell research funding enabled by Proposition 71, are aiming for clinical trials involving gene therapy through bone marrow transplants.Clad in a yellow gown, blue foot covers, hair net, face mask and latex gloves, Paula Cannon pushed open the door to the animal room. "I hate this smell," she said, wrinkling her nose. (Source: L.A. Times - Health)...
POSTED 08/21/2010 at 08:44 PM --
|
Immunotherapy of Cancer
Methods and Protocolsseries:Methods in Molecular BiologyA continuously evolving technique, immunotherapy for the treatment of cancers now incorporates the use of immune cells infused during bone marrow transplants as well as approaches like cell and gene therapy, while stem cell-based therapies, tissue engineering, and targeting have also contributed to the latest successes in pre-clinical immunotherapy studies. In Immunotherapy of Cancer: Methods ... (Source: Springer Biomedical Sciences titles)...
POSTED 08/21/2010 at 02:23 AM --
|
Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox
Conclusions:
In conclusion, these data provide critical information to justify further investigation into the potential use of these compounds post allogeneic bone marrow transplantation to alleviate graft-versus-host disease thereby achieving better outcomes. (Source: Journal of Inflammation)...
POSTED 08/17/2010 at 06:00 PM --
|
Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia
In this study, we attempted to assess the interactions of resveratrol, a natural compound present in various plant species,
with the purine analogues fludarabine and cladribine in terms of their effects on DNA damage and apoptosis in chronic lymphocytic
leukemia (CLL) cells. The experiments were performed ex vivo using short-term cell cultures of blood and bone marrow cells
from newly diagnosed untreated patients. We analyzed the expression of active caspase-3 and the BCL-2/BAX ratio as markers
of apoptosis and the expression of phosphorylated histone H2AX (γH2AX) and activated ATM kinase, which are reporters of DNA
damage. The results of our study revealed that resveratrol induced apoptosis in CLL cells in a tumor-specific manner but did
not affect non-leukemic cells, and apoptosis......
POSTED 08/16/2010 at 01:02 PM --
|
Mesoblast Limited (ASX:MSB) On Track For Phase 3 Bone Marrow Transplant Trial Following Positive Meeting With United States FDA
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided market guidance on its Phase 3 bone! marrow transplant program following a formal meeting with the! United States Food and Drug Administration (FDA). For this Phase 3 program, the patented allogeneic, or "off-the-shelf", adult Mesenchymal Precursor Cells (MPCs) will be used under a United States FDA Orphan Drug Designation to expand unrelated donor haematopoietic stem and progenitor cell numbers for use in patients with haematologic malignancies... (Source: Health News from Medical News Today)...
POSTED 08/16/2010 at 04:00 AM --
|
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
Bone Marrow Transplantation advance online publication, August 16, 2010. doi:10.1038/bmt.2010.190
Authors: J Pidala, J Kim, C Anasetti, M A Kharfan-Dabaja, T Field, J Perkins, E Ayala, L Perez,
& H Fernandez (Source: Bone Marrow Transplantation)...
POSTED 08/15/2010 at 06:00 PM --
|
Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility
Authors: Y Wang, L P Xu, K Y Liu, D H Liu, J Wang, H Chen, Y H Chen, W Han
& X J Huang (Source: Bone Marrow Transplantation)...
POSTED 08/15/2010 at 06:00 PM --
|
Stem cell transplantation shows promise for dystrophic epidermolysis bullosa
Initial study results suggest that bone marrow transplantation shows promise for the treatment of children with severe recessive dystrophic epidermolysis bullosa. (Source: MedWire News - Pediatrics)...
POSTED 08/14/2010 at 02:11 AM --
|
Stem cell transplantation shows promise for dystrophic epidermolysis bullosa
Initial study results suggest that bone marrow transplantation shows promise for the treatment of children with severe recessive dystrophic epidermolysis bullosa. (Source: MedWire News - Dermatology)...
POSTED 08/14/2010 at 12:38 AM --
|
Marrow Transplant Risky -- But May Help Rare Skin Disease (CME/CE)
(MedPage Today) -- Bone marrow transplantation may help fight a rare genetic blistering skin disease -- but could be too risky for any but the severest cases, according to a small study. (Source: MedPage Today Dermatology)...
POSTED 08/11/2010 at 10:13 PM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
Featured Product! |
 |
|
Arthrit-Eze |
|
Arthrit-Eze is the most advanced
formula on the market today |
|
It offers potential relief and
rejuvenation for all forms of arthritis, safely, naturally and without side
effects!
NO PRESCRIPTION REQUIRED! |
|
CLICK HERE
for more info... |
|
|
